Table 2 Interventional traits and dosage regimen of the extracellular vesicle therapy
Question of interest | Example answers |
|---|---|
Storage of EVs | Frozen at – 80 °C |
Fresh / fridge | |
Not described | |
Tissue source of MSCs | Bone marrow |
Adipose | |
Umbilical cord/Wharton’s jelly | |
Animal source of MSCs | Human source |
Mouse source | |
Rat source | |
EV immunocompatibility | Xenogeneic |
Allogeneic | |
Autologous | |
Not described | |
Modification of EVs | Unmodified |
Modified MSCs before EV isolation | |
Modified EVs directly | |
Route of administration | Intravenous |
Direct tissue injection | |
Subcutaneous | |
Intra-arterial | |
EV dosage units | EV protein amount |
EV particle number | |
EV dose based on MSC cell count | |
Timing of First EV dose | Post-injury induction (treatment) |
Pre-injury induction (prevention) | |
Number of doses used | Single dose of EVs |
Multiple doses of EVs |